ID   EB3 [Human Burkitt lymphoma]
AC   CVCL_1185
SY   EB-3; Epstein-Barr-3; GM04679
DR   CLO; CLO_0002874
DR   CLO; CLO_0019013
DR   EFO; EFO_0002174
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473119
DR   cancercelllines; CVCL_1185
DR   CCRID; 1101HUM-PUMC000343
DR   Cell_Model_Passport; SIDM00793
DR   CGH-DB; 9198-4
DR   ChEMBL-Cells; CHEMBL3308824
DR   ChEMBL-Targets; CHEMBL2366369
DR   CLS; 300373
DR   Coriell; GM04679
DR   Cosmic; 687840
DR   Cosmic; 906847
DR   Cosmic; 1818343
DR   Cosmic-CLP; 906847
DR   DepMap; ACH-002236
DR   ECACC; 90121003
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 906847
DR   GEO; GSM1669748
DR   IARC_TP53; 155
DR   IARC_TP53; 21145
DR   IGRhCellID; EB3
DR   JCRB; IFO50028
DR   PharmacoDB; EB3_312_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1185
DR   PubChem_Cell_line; CVCL_1185
DR   Wikidata; Q54831748
RX   CelloPub=CLPUB00447;
RX   DOI=10.1007/BF02618370;
RX   PubMed=2052620;
RX   PubMed=2985879;
RX   PubMed=2998993;
RX   PubMed=3159941;
RX   PubMed=3518877;
RX   PubMed=3874327;
RX   PubMed=4169243;
RX   PubMed=4342611;
RX   PubMed=4736620;
RX   PubMed=4894370;
RX   PubMed=5884338;
RX   PubMed=6018567;
RX   PubMed=6286763;
RX   PubMed=7316467;
RX   PubMed=8515068;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Problematic cell line: Partially contaminated. Some stocks (such as IFO50028) were contaminated by Daudi.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00380.
CC   Population: African; Ugandan.
CC   Doubling time: 48 hours (PubMed=5884338).
CC   HLA typing: A*03:01,30:02; B*15:03,47:03; C*02:02,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Heterozygous (Cosmic-CLP=906847; DepMap=ACH-002236).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn345Argfs*24 (c.1034_1037del); Zygosity=Heterozygous (Cosmic-CLP=906847; DepMap=ACH-002236).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1101-2A>G; ClinVar=VCV000141332; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP=906847; DepMap=ACH-002236).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=83.99%; Native American=0.51%; East Asian, North=5.96%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=9.53% (PubMed=30894373).
CC   Discontinued: JCRB; IFO50028; true.
CC   Derived from site: In situ; Bone, jaw, maxilla; UBERON=UBERON_0002397.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): ATCC=CCL-85; CCRID=1101HUM-PUMC000343; CLS=300373; Cosmic-CLP=906847; ECACC=90121003; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 12,15
ST   D12S391: 15
ST   D13S317: 12,14
ST   D16S539: 10,12
ST   D18S51: 15,17
ST   D19S433: 12.2,16.2
ST   D21S11: 29
ST   D2S1338: 17,22
ST   D3S1358: 15,16
ST   D5S818: 9,10
ST   D6S1043: 11,13
ST   D7S820: 11
ST   D8S1179: 14
ST   FGA: 22
ST   Penta D: 10,11
ST   Penta E: 14,16
ST   TH01: 7
ST   TPOX: 6,9
ST   vWA: 16,17,19 (Cosmic-CLP=906847)
ST   vWA: 17,19 (ATCC=CCL-85; CCRID=1101HUM-PUMC000343; CLS=300373; ECACC=90121003; PubMed=25877200)
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 43
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
RX   DOI=10.1007/BF02618370;
RA   Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.;
RT   "The animal cell culture collection.";
RL   In Vitro 5:1-16(1970).
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
RX   PubMed=2998993;
RA   Steel C.M., Morten J.E.N., Foster E.;
RT   "The cytogenetics of human B lymphoid malignancy: studies in Burkitt's
RT   lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell
RT   lines.";
RL   IARC Sci. Publ. 60:265-292(1985).
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C.";
RL   Leuk. Res. 9:549-559(1985).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
RX   PubMed=4169243; DOI=10.1093/jnci/39.5.1027;
RA   Klein G., Clifford P., Klein E., Smith R.T., Minowada J.,
RA   Kourilsky F.M., Burchenal J.H.;
RT   "Membrane immunofluorescence reactions of Burkitt lymphoma cells from
RT   biopsy specimens and tissue cultures.";
RL   J. Natl. Cancer Inst. 39:1027-1044(1967).
RX   PubMed=4342611; DOI=10.1136/jcp.25.8.701;
RA   Marston S.D., Almond E.J.P., Bishun N.P., Maunsell E.D., Sutton R.N.P.;
RT   "A 'virus-free' cell line derived from a patient with infectious
RT   mononucleosis.";
RL   J. Clin. Pathol. 25:701-704(1972).
RX   PubMed=4736620; DOI=10.1111/j.1469-1809.1973.tb00588.x;
RA   Povey S., Gardiner S.E., Watson B., Mowbray S., Harris H., Arthur E.,
RA   Steel C.M., Blenkinsop C., Evans H.J.;
RT   "Genetic studies on human lymphoblastoid lines: isozyme analysis on
RT   cell lines from forty-one different individuals and on mutants
RT   produced following exposure to a chemical mutagen.";
RL   Ann. Hum. Genet. 36:247-266(1973).
RX   PubMed=4894370; DOI=10.1002/1097-0142(196908)24:2<211::AID-CNCR2820240202>3.0.CO;2-3;
RA   Southam C.M., Burchenal J.H., Clarkson B.D. Sr., Tanzi A., Mackey R.,
RA   McComb V.;
RT   "Heterotransplantability of human cell lines derived from leukemia and
RT   lymphomas into immunologically tolerant rats.";
RL   Cancer 24:211-222(1969).
RX   PubMed=5884338;
RA   Epstein M.A., Barr Y.M., Achong B.G.;
RT   "Studies with Burkitt's lymphoma.";
RL   Wistar Inst. Symp. Monogr. 4:69-82(1965).
RX   PubMed=6018567;
RA   Miles C.P., O'Neill F.;
RT   "Chromosome studies of 8 in vitro lines of Burkitt's lymphoma.";
RL   Cancer Res. 27:392-402(1967).
RX   PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).